These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 20378262)

  • 1. Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.
    Maguire PD; Papagikos M; Hamann S; Neal C; Meyerson M; Hayes N; Ungaro P; Kotz K; Couch M; Pollock H; Tepper J
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1081-8. PubMed ID: 20378262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
    Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
    Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
    Dirix P; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity.
    Hoffmann M; Saleh-Ebrahimi L; Zwicker F; Haering P; Schwahofer A; Debus J; Huber PE; Roeder F
    Radiat Oncol; 2015 Dec; 10():251. PubMed ID: 26637471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
    Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
    Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
    Leyvraz S; Pasche P; Bauer J; Bernasconi S; Monnier P
    J Clin Oncol; 1994 Sep; 12(9):1876-85. PubMed ID: 8083711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.
    Espeli V; Zucca E; Ghielmini M; Giannini O; Salatino A; Martucci F; Richetti A
    Oral Oncol; 2012 Mar; 48(3):266-71. PubMed ID: 22079100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
    Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
    Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
    de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
    Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
    Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
    Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
    Hehr T; Classen J; Belka C; Welz S; Schäfer J; Koitschev A; Bamberg M; Budach W
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1423-31. PubMed ID: 15817346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
    Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
    Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.